Who
Iain Stuart
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, VYNE Therapeutics; Chief Scientific Officer, Foamix Pharmaceuticals.
In numbers
- Trades disclosed
- 73
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $27K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 27 Feb 2018
- Last trade
- 23 Jul 2026
- Last filed
- 24 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jul 2026filed 24 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $14K15,405 at $0.8976 | filing |
| 23 Jul 2026filed 24 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $14K15,405 at $0.90 | filing |
| 30 Jun 2026filed 2 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,5422,370 at $0.6507 | filing |
| 30 Jun 2026filed 2 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,5412,370 at $0.65 | filing |
| 31 Mar 2026filed 2 Apr 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,7182,876 at $0.5975 | filing |
| 31 Mar 2026filed 2 Apr 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,7262,876 at $0.60 | filing |
| 31 Dec 2025filed 5 Jan 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,4202,448 at $0.5801 | filing |
| 31 Dec 2025filed 5 Jan 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,4202,448 at $0.58 | filing |
| 30 Sep 2025filed 2 Oct 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $8342,453 at $0.34 | filing |
| 30 Jun 2025filed 2 Jul 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,0472,453 at $1.65 | filing |
| 31 Mar 2025filed 2 Apr 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $9,5506,044 at $1.58 | filing |
| 21 Jan 2025filed 23 Jan 2025 | VYNE Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 31 Dec 2024filed 2 Jan 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $16K4,857 at $3.35 | filing |
| 30 Sep 2024filed 2 Oct 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $205109 at $1.88 | filing |
| 1 Jul 2024filed 3 Jul 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $265138 at $1.92 | filing |
| 1 Apr 2024filed 3 Apr 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $484157 at $3.08 | filing |
| 2 Jan 2024filed 3 Jan 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $358157 at $2.28 | filing |
| 1 Jan 2024filed 3 Jan 2024 | VYNE Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 13 Dec 2023filed 15 Dec 2023 | VYNE Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.